How I treat: Diagnostic clues and treatment for activated phosphoinositide 3-kinase delta syndrome
Journal of Human Immunity · 07.09.2026 · 2 (5)
DOI: 10.70962/jhi.20260054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Human Immunity, online erschienen am 27.07.2026. Verfasst von Hirokazu Kanegane und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Activated phosphoinositide 3-kinase delta syndrome (APDS) is a form of common variable immunodeficiency (CVID) caused by gain-of-function variants in PIK3CD (APDS1) or loss-of-function variants in PIK3R1 (APDS2), resulting in hyperactivation of the PI3Kδ pathway. Clinically, it is characterized by recurrent respiratory infections, lymphadenopathy, splenomegaly, and progressive airway destruction, often leading to bronchiectasis. Enteropathy, cytopenia, and immune dysregulation have also been observed in several patients. Some patients develop malignant lymphomas, which can be fatal. Prophylactic antimicrobial therapy and regular immunoglobulin replacement therapy are administered in a manner similar to that used for CVID. However, since excessive activation of the class IA phosphoinositide 3-kinase signaling pathway is the primary pathophysiology of APDS, mammalian target of rapamycin inhibitors and selective p110δ inhibitors are expected to be licensed therapies. Early diagnosis based on diagnostic clues specific to APDS, followed by prompt treatment, is expected to improve patient prognosis.
Autor:innen und Institutionen
- Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- Department of Pediatrics, Hiroshima University Graduate School of Medicine and Health Sciences, Hiroshima, Japan.
ORCID-Profile: Hirokazu Kanegane, Dan Tomomasa, Satoshi Okada
Zitieren
APA
Kanegane, H., Tomomasa, D., & Okada, S. (2026). How I treat: Diagnostic clues and treatment for activated phosphoinositide 3-kinase delta syndrome. Journal of Human Immunity, 2(5). https://doi.org/10.70962/jhi.20260054
Vancouver
Kanegane H, Tomomasa D, Okada S. How I treat: Diagnostic clues and treatment for activated phosphoinositide 3-kinase delta syndrome. Journal of Human Immunity. 2026;2(5). doi:10.70962/jhi.20260054
BibTeX
@article{Kanegane2026,
author = {Kanegane, Hirokazu and Tomomasa, Dan and Okada, Satoshi},
title = {How I treat: Diagnostic clues and treatment for activated phosphoinositide 3-kinase delta syndrome},
journal = {Journal of Human Immunity},
year = {2026},
volume = {2},
number = {5},
doi = {10.70962/jhi.20260054}
}
EUVIMED